Deoxy-uridin | 951-78-0

• 物质功能分类: 生物化工 - 核苷类药物 - 核苷酸及其类似物
• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: Deoxy-uridin
• 英文别名: 1-[(4R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
• CAS: 951-78-0；4449-42-7；4481-11-2；13039-99-1；31501-19-6；41545-92-0；41546-05-8；88494-09-1
• 化学式: C₉H₁₂N₂O₅
• 分子量: 228.205
• InChiKey: MXHRCPNRJAMMIM-SDUJUNFKSA-N

物化性质

• 熔点：
  167-169 °C(lit.)
• 比旋光度：
  D22 +50° (c = 1.1 in N NaOH)
• 沸点：
  370.01°C (rough estimate)
• 密度：
  1.3705 (rough estimate)
• 溶解度：
  DMSO（轻微）、甲醇（轻微、加热）、水（轻微）

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  99.1
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• TSCA：
  Yes
• 危险品标志：
  Xn
• 安全说明：
  S22,S24/25,S37/39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  29349990
• 危险品运输编号：
  NONH for all modes of transport
• RTECS号：
  YU7490000
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

制备方法与用途

简介

2′-脱氧鸟苷是一种天然的脱氧核苷，可以直接用于制备组合脱氧核苷药物或作为化学试剂用于生化研究。此外，它还可以用作合成某些抗病毒核苷类药物及分子标记物的中间体。例如，可以利用2′-脱氧鸟苷原料合成8-溴-2′-脱氧鸟苷和8-羟基-2′-脱氧鸟苷等重要分子标记物；同时，也能合成2′-脱氧鸟苷6位衍生物，如6-甲氧基、6-氨基等系列重要的抗肿瘤药物。

用途

2-脱氧尿苷可用于治疗过敏、癌症、感染及自身免疫性疾病。

生物活性

2′-Deoxyuridine 能促使染色体断裂，并降低 thymidylate 的合成活性，同时也是合成分解产物 edoxudine 的前体。

靶点

Human Endogenous Metabolite

用途是生产抗肿瘤药FUDR、抗病毒药IDUR与BrDUR的原料药，并用作生化试剂。此外，还用于合成酶抑制剂、抗病毒剂及抗癌剂。

文献信息

• Modulators of DUX4 for regulation of muscle function
  申请人：GENEA BIOCELLS USA (HOLDINGS), INC.

  公开号：US10933068B2

  公开（公告）日：2021-03-02

  Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases or disorders. In some cases, the methods and compositions involve the use of methyltransferase inhibitors to inhibit or repress DUX4 expression in muscle cells. Further disclosed herein are methods and cell based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases.

  本文公开了治疗面肱骨肌营养不良症和其他肌肉疾病或紊乱的方法和组合物。在某些情况下，这些方法和组合物涉及使用甲基转移酶抑制剂来抑制或抑制肌肉细胞中 DUX4 的表达。本文进一步公开了用于筛选治疗面阔肌营养不良症和其他肌肉疾病的化合物的方法和基于细胞的检测方法。
• MODULATORS OF DUX4 FOR REGULATION OF MUSCLE FUNCTION
  申请人：GENEA BIOCELLS USA (HOLDING), INC.

  公开号：US20190298727A1

  公开（公告）日：2019-10-03

  Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases or disorders. In some cases, the methods and compositions involve the use of methyltransferase inhibitors to inhibit or repress DUX4 expression in muscle cells. Further disclosed herein are methods and cell based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases.
• PROTON ACTIVATED ATOMIC MEDICINE
  申请人：University of Virginia Patent Foundation

  公开号：US20210024564A1

  公开（公告）日：2021-01-28

  The present application provides compositions and methods for preparing and using “heavy” nucleotide derivatives of thymidine or uridine by replacing the oxygen atom attached to one or more of positions with non-radioactive oxygen-18 ( 18 O), administering it to a subject to target a tumor including incorporation into tumor cell DNA, and then treating the tumor with proton beam therapy to transmutate the 18 O to 18 F, resulting in a break of the new fluorine-phosphorous bond. This chemical event destabilizes ribose-phosphate DNA back-bone and base pairing thus produce single- and double strand breaks, clusters lesions that can lead to irreparable DNA damage and enhanced tumor cell killing. The atomic, chemical, and physical aspects result in the use of lower radiation doses and significantly alter acute and late morbidity of radiotherapy. Heavy thymidine and heavy uridine derivatives labeled with 18 O have been made and tested.
• Modulators of DUX4 for Regulation of Muscle Function
  申请人：Sonic Master Limited

  公开号：US20210196723A1

  公开（公告）日：2021-07-01

  Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases or disorders. In some cases, the methods and compositions involve the use of methyltransferase inhibitors to inhibit or repress DUX4 expression in muscle cells. Further disclosed herein are methods and cell-based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases.
• US9885082B2
  申请人：——

  公开号：US9885082B2

  公开（公告）日：2018-02-06